Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Ignacio Garrido‐Laguna

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2273-9028; OpenAlex author ID A5029563022; NIH RePORTER profile ID 11747760. Sources: ClinicalTrials.gov.

Their work

Papers
37 (first author 5, last author 10)
Trials
1 (principal investigator on 1)
Grants
1
Labs led
2
Collaborators
132
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: none · 2014: 1 trial · 2015: 2 papers, 1 grant · 2016: none · 2017: 1 paper · 2018: 5 papers · 2019: 1 paper · 2020: 4 papers · 2021: 6 papers · 2022: 1 paper · 2023: 5 papers · 2024: 4 papers · 2025: 2 papers · 2026: 3 papers

Papers 37

  1. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Co-author DOI 10.1038/s41591-026-04537-w↗
  2. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2505783↗
  3. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2605555↗
  4. KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamanetworkopen.2024.53588↗
  5. Gemcitabine-induced myositis in a patient with pancreatic cancer. Last author DOI 10.1136/bcr-2024-259660↗
  6. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? First author DOI 10.1038/s41571-024-00896-w↗
  7. Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'. Last author DOI 10.1038/s41571-024-00953-4↗
  8. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.013↗
  9. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Me… Co-author DOI 10.3390/cancers16071323↗
  10. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP … Co-author DOI 10.1016/j.esmoop.2023.101584↗
  11. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2208470↗
  12. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations … Last author DOI 10.1158/1078-0432.ccr-22-3724↗
  13. Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltrat… Last author DOI 10.1158/1078-0432.ccr-23-0535↗
  14. Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/cci.22.00160↗
  15. Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. Last author DOI 10.1186/s12885-022-10130-4↗
  16. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcino… Co-author DOI 10.1016/j.neo.2021.06.005↗
  17. Therapeutic Targeting of Autophagy in Pancreatic Cancer. First author DOI 10.1016/j.soc.2021.06.001↗
  18. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001844↗
  19. Emerging Treatment Strategies in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001845↗
  20. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: … Co-author DOI 10.1158/1078-0432.ccr-21-1789↗
  21. Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1177/17588359211045861↗
  22. The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. First author DOI 10.1002/cam4.2851↗
  23. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Last author DOI 10.1038/s41571-019-0281-6↗
  24. Metastatic Pancreatic Cancer: ASCO Guideline Update. Co-author DOI 10.1200/jco.20.01364↗
  25. Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. Last author DOI 10.1200/po.20.00052↗
  26. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative … Co-author DOI 10.1007/s11605-018-3953-0↗
  27. Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. First author DOI 10.1136/esmoopen-2017-000282↗
  28. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.2018.78.9636↗
  29. Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. First author DOI 10.1200/po.18.00039↗
  30. Large database utilization in health outcomes research in pancreatic cancer: an update. Co-author DOI 10.21037/jgo.2018.05.15↗
  31. Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. Co-author DOI 10.21037/jgo.2018.05.16↗
  32. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Co-author DOI 10.1002/cncr.30780↗
  33. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Co-author DOI 10.1038/nrclinonc.2015.53↗
  34. N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Co-author DOI 10.18632/oncoscience.141↗
  35. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic … Co-author DOI 10.1158/1078-0432.ccr-11-0341↗
  36. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Co-author DOI 10.1158/1535-7163.mct-10-0893↗
  37. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Co-author DOI 10.4161/cbt.12.7.16475↗

Trials 1

  1. A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer Principal investigator NCT01911416↗

Grants 1

  1. Multi-Tracer PET/CT Imaging of Gemcitabine Response in Pancreatic Cancer R21CA182977↗

Closest collaborators

The 25 strongest of 132 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chris Nevala-Plagemann · 11 shared papers, 2020–2025 · strength 2.66
  2. Vaia Florou · 5 shared papers, 2020–2025 · strength 1.11
  3. Kajsa E. Affolter · 5 shared papers, 2020–2024 · strength 0.72
  4. Brian Matthew Wolpin · 3 shared papers, 2026 · strength 0.64
  5. Zach Rubnitz · 2 shared papers, 2025 · strength 0.63
  6. Courtney L. Scaife · 5 shared papers, 2018–2023 · strength 0.61
  7. Shane A. J. Lloyd · 6 shared papers, 2017–2020 · strength 0.60
  8. David S. Hong · 3 shared papers, 2023–2026 · strength 0.54
  9. Sean J. Mulvihill · 4 shared papers, 2019–2024 · strength 0.53
  10. Nathan Bahary · 3 shared papers, 2023–2024 · strength 0.51
  11. Nilofer Saba Azad · 2 shared papers, 2026 · strength 0.46
  12. Thierry Conroy · 2 shared papers, 2020–2024 · strength 0.45
  13. Philip A. Philip · 4 shared papers, 2018–2024 · strength 0.43
  14. Heloisa Prado Soares · 2 shared papers, 2023–2025 · strength 0.43
  15. Zev A. Wainberg · 2 shared papers, 2024–2026 · strength 0.42
  16. Alexander Starodub · 2 shared papers, 2026 · strength 0.41
  17. Wungki Park · 2 shared papers, 2026 · strength 0.41
  18. Minal A. Barve · 2 shared papers, 2026 · strength 0.41
  19. Alexander I. Spira · 2 shared papers, 2026 · strength 0.41
  20. Eileen Mary O'Reilly · 3 shared papers, 2018–2026 · strength 0.38
  21. Anna M. Torgeson · 4 shared papers, 2017–2018 · strength 0.38
  22. Manuel M. Hidalgo · 5 shared papers, 2011–2020 · strength 0.36
  23. Teresa Mercade Macarulla · 2 shared papers, 2021–2024 · strength 0.35
  24. Laura K. Miotke · 2 shared papers, 2021–2022 · strength 0.34
  25. Andrea Wang‐Gillam · 2 shared papers, 2023–2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.